Belvedere Trading’s Crescent Biopharma CBIO Stock Holding History

Belvedere Trading’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-36	Closed	-$10.8K	–	780
2024 Q1	$10.8K	Buy	+36	New	+$10.8K	﹤0.01%	602

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Belvedere Trading's CBIO Position: Q2 2024 in Review

Belvedere Trading sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 205 shares — an estimated $61.4K sold.

Belvedere Trading first reported a position in CBIO in Q1 2024 and held it in 1 quarter. The position peaked at $61.4K in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

Belvedere Trading reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
Belvedere Trading sold 205 Crescent Biopharma shares in Q2 2024, an estimated $61.4K.
Belvedere Trading first reported a position in Crescent Biopharma in Q1 2024 and held it in 1 quarter.
Belvedere Trading's Crescent Biopharma position peaked at $61.4K in Q1 2024.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.